Clearmind Medicine Inc., a clinical-stage biotech company, has announced the expansion of its ongoing Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD) with the inclusion of Tel Aviv Sourasky Medical Center in Israel. The trial is evaluating CMND-100, a proprietary MEAI-based oral drug candidate. The enrollment of the first patient was completed earlier this month. The study at Tel Aviv Sourasky Medical Center will be led by Dr. David Zeltser. This expansion includes other prestigious institutions such as Yale School of Medicine and Johns Hopkins University School of Medicine. The trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while exploring its potential to reduce alcohol cravings and consumption in patients with AUD. Results from the trial have not yet been presented.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。